T2 Biosystems, Inc. (NASDAQ:TTOO) – Research analysts at Leerink Swann reduced their Q1 2017 earnings estimates for T2 Biosystems in a report issued on Tuesday. Leerink Swann analyst P. Souda now expects that the firm will post earnings of ($0.59) per share for the quarter, down from their previous forecast of ($0.49). Leerink Swann has a “Market Perform” rating and a $5.00 price objective on the stock. Leerink Swann also issued estimates for T2 Biosystems’ Q2 2017 earnings at ($0.59) EPS, Q3 2017 earnings at ($0.57) EPS, Q4 2017 earnings at ($0.56) EPS, FY2017 earnings at ($2.31) EPS, Q1 2018 earnings at ($0.54) EPS, Q2 2018 earnings at ($0.54) EPS, Q3 2018 earnings at ($0.51) EPS, Q4 2018 earnings at ($0.47) EPS, FY2018 earnings at ($2.05) EPS and FY2019 earnings at ($1.21) EPS.

“Leerink Swann Brokers Cut Earnings Estimates for T2 Biosystems, Inc. (TTOO)” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at http://www.watchlistnews.com/leerink-swann-brokers-cut-earnings-estimates-for-t2-biosystems-inc-ttoo/1120788.html.

Earnings History and Estimates for T2 Biosystems (NASDAQ:TTOO)

Several other equities analysts also recently issued reports on the company. Cantor Fitzgerald cut their price objective on T2 Biosystems from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, November 2nd. Zacks Investment Research upgraded T2 Biosystems from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a research report on Saturday, November 5th. WBB Securities reiterated a “buy” rating and issued a $12.00 price objective on shares of T2 Biosystems in a research report on Sunday, February 5th. Finally, Canaccord Genuity set a $9.00 price objective on T2 Biosystems and gave the company a “buy” rating in a research report on Monday, January 23rd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. T2 Biosystems presently has a consensus rating of “Hold” and a consensus price target of $7.21.

T2 Biosystems (NASDAQ:TTOO) traded up 4.35% on Thursday, hitting $6.00. The stock had a trading volume of 58,668 shares. T2 Biosystems has a 1-year low of $4.89 and a 1-year high of $11.30. The firm’s 50-day moving average price is $5.45 and its 200-day moving average price is $6.24. The firm’s market cap is $182.59 million.

Several large investors have recently added to or reduced their stakes in the company. State Street Corp increased its stake in T2 Biosystems by 2.7% in the fourth quarter. State Street Corp now owns 195,138 shares of the company’s stock worth $1,027,000 after buying an additional 5,205 shares during the last quarter. Lagoda Investment Management L.P. purchased a new stake in T2 Biosystems during the third quarter worth $13,625,000. Tiger Management L.L.C. increased its stake in T2 Biosystems by 5.0% in the third quarter. Tiger Management L.L.C. now owns 1,307,639 shares of the company’s stock worth $9,467,000 after buying an additional 62,501 shares during the last quarter. Senvest Management LLC increased its stake in T2 Biosystems by 14.9% in the third quarter. Senvest Management LLC now owns 1,898,080 shares of the company’s stock worth $13,742,000 after buying an additional 246,849 shares during the last quarter. Finally, Flagship Ventures Fund IV General Partner LLC purchased a new stake in T2 Biosystems during the second quarter worth $5,852,000. Institutional investors own 68.08% of the company’s stock.

“Leerink Swann Brokers Cut Earnings Estimates for T2 Biosystems, Inc. (TTOO)” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at http://www.watchlistnews.com/leerink-swann-brokers-cut-earnings-estimates-for-t2-biosystems-inc-ttoo/1120788.html.

T2 Biosystems Company Profile

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

5 Day Chart for NASDAQ:TTOO

Receive News & Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.